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A bstract
Background: Previous studies have extensively documented antimicrobial and chemotactic activities of beta-defensins. 
Human beta-defensin-2 (hBD-2) is strongly expressed in lesional psoriatic epidermis, and recently we have shown that high 
beta-defensin genomic copy number is associated with psoriasis susceptibility. It is not known, however, if biologically and 
pathophysiologically relevant concentrations of hBD-2 protein are present in vivo, which could support an antimicrobial and 
proinflammatory role of beta-defensins in lesional psoriatic epidermis.
M ethodoiogy/PrincipaiFindings: We found that systemic levels of hBD-2 showed a weak but significant correlation with 
beta defensin copy number in healthy controls but not in psoriasis patients with active disease. In psoriasis patients but not 
in atopic dermatitis patients, we found high systemic hBD-2 levels that strongly correlated with disease activity as assessed 
by the PASI score. Our findings suggest that systemic levels in psoriasis are largely determined by secretion from involved 
skin and not by genomic copy number. Modelling of the in vivo epidermal hBD-2 concentration based on the secretion rate 
in a reconstructed skin model for psoriatic epidermis provides evidence that epidermal hBD-2 levels in vivo are probably 
well above the concentrations required for in vitro antimicrobial and chemokine-like effects.
Conclusions/Significance: Serum hBD-2 appears to be a useful surrogate marker for disease activity in psoriasis. The 
discrepancy between hBD-2 levels in psoriasis and atopic dermatitis could explain the well known differences in infection 
rate between these two diseases.
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Introduction
Psoriasis is a highly prevalent inflammatory skin disease that has 
both environmental and genetic components to its etiology [1,2]. 
Genetic evidence for an (auto)immune basis of psoriasis is 
provided by the well-known association of the disease with the 
HLA-Cw6 gene [3] and the recently discovered associations with 
IL12B and IL23R [4,5]. Lesional psoriatic skin is characterized by 
various morphological abnormalities of the epidermis, and a 
cellular infiltrate of activated T-cells. There are several arguments 
to invoke an im portant role of activated T-cells such as the 
oligoclonal T-cell expansion in psoriatic skin [6] and the
therapeutic efficacy of T-cell directed drugs such as cyclosporin 
A and some of the biologics that are currently available. Recent 
evidence also points to a role of other cell types such as 
plasmacytoid dendritic cells [7], and cytokine networks associated 
with cells from the adaptive and innate immune system [1,8]. 
Based on clinical studies in humans and experimental studies in 
mice, several of these cytokines have been identified including IL-
1, TN Fa, interferon-c and IL-6. In the epidermis a regenerative 
epidermal differentiation program is induced that includes 
hyperproliferation and expression of genes such as cytokeratin 
16 (CK16), SKALP/elafin, psoriasin and hBD-2 [9,10]. Expres­
sion of these genes is to some extent specific for psoriasis, as they
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are expressed at low levels, if at all, in lesional atopic dermatitis 
skin [11-13].
Recent findings from various labs including our own have 
indicated that polymorphisms of genes that are expressed in the 
epithelium, but not necessarily in immunocytes, could also be risk 
factors for inflammatory skin diseases such as atopic dermatitis and 
psoriasis [14-17]. This finding was further supported at the 
cellular level when we found cell-autonomous differences between 
keratinocytes from psoriasis and atopic dermatitis patients [18]. 
From these studies we concluded that psoriatic keratinocytes are 
programmed to secrete large amounts of host defense proteins 
such as beta-defensins, in response to Th1 or Th17 cytokines.
Beta-defensins are secreted peptides of low molecular weight 
ranging from 3 to 5 kDa. These peptides, which are expressed by 
epithelia, possess a broad spectrum of antimicrobial activity 
against both gram-positive and gram-negative bacteria, fungi and 
viruses [19]. Besides antimicrobial activity, they also exhibit pro- 
inflammatory properties as chemoattractants for memory T-cells, 
immature dendritic cells, mast cells and neutrophils [20-22]. 
These peptides, encoded by the DEFB genes, are present in three 
main gene clusters, two on chromosome 20 and one on 8p23.1. 
The cluster on 8p23.1 contains eight beta-defensin genes of which 
seven (all but DEFBI) are on a large repeat that is variable in copy 
number. In humans up to 12 copies of this repeat have been 
found, with a mode of four copies per diploid genome [23]. O f the 
eight beta-defensin genes located on 8p23.1, hum an beta-defensin-
1 (hBD-1) protein, (encoded by DEFBI) and hBD-3 (encoded by 
DEFB103) are constitutively expressed at low levels in skin [24]. 
hBD-2 (encoded by DEFB4) is not expressed in normal skin but is 
highly expressed in psoriatic skin. hBD-4 (encoded by DEFB104) is 
less well characterized at the protein level but is found in skin by 
RT-PCR. hBD-2, hBD-3 and hBD-4 can be induced by cytokines 
and bacterial lipopolysaccharides in various epithelial cell types 
[25]. It has also been shown that antimicrobial peptides in general, 
and above all hBD-2, are induced in lesional epidermal cells of 
patients with psoriasis, compared with lesional epidermal cells of 
patients with atopic dermatitis and normal skin [10,11]. These 
findings have been interpreted to explain the observed high 
infection rate in atopic dermatitis and the relatively low prevalence 
of bacterial and viral infections among psoriasis patients [26].
In addition to their direct antimicrobial activity, the chemotactic 
properties of antimicrobial proteins like LL-37 and beta-defensins 
are thought to amplify leukocyte recruitment [27], thereby 
contributing to an effective antimicrobial response. In non- 
infectious inflammatory diseases like psoriasis, beta-defensins 
could augment the influx of T-cells and dendritic cells, and 
thereby contribute to chronicity and sustained disease. Although 
the antimicrobial and chemotactic activities in vitro have been well 
documented, there are no quantitative data on in vivo concentra­
tions of beta-defensins to substantiate a role of these molecules in 
host defense or inflammation. In this study we have made a 
detailed analysis of systemic and epidermal defensin concentra­
tions. We show that both genetic factors and disease activity 
determine defensin protein expression. Evidence is provided that 
the in vivo concentration of hBD-2 is well above the minimal 
concentrations that are required for biological activity in vitro.
M aterials and M ethods
Patients and healthy subjects
All psoriasis patients had plaque-type psoriasis diagnosed by a 
dermatologist. Atopic dermatitis was diagnosed by a dermatolo­
gist, according to the Hanifin criteria, and were of the extrinsic 
type [28]. Rheumatoid arthritis patients were diagnosed by a
rheumatologist, according to the ACR criteria. Patients were 
recruited via the in-patient or out-patient departments of the 
Radboud University Nijmegen Medical Centre. Control sera and 
DNA samples were from the Nijmegen Biomedical Study (NBS) 
[29]. All controls and patients were of native European Dutch 
origin. Demographic data were as follows (age: mean and SD, and 
% female); Controls: 50616 , 59% female; Psoriasis patients: 
47613  year, 42% female; Rheumatoid arthritis patients: 
59 6 8  years, 66% female. Available information of medication 
used during sample collection: 59% of the psoriasis patients were 
on biologicals (all TNF-blockers) and 36% were on other types of 
systemic medication (retinoids, MTX). Nearly all rheumatoid 
arthritis patients used NSAIDs, 45% was on M T X  and 25% was 
on biologicals (various kinds, mostly TNF blockers). Blood was 
stored at — 80°C and genomic DNA was isolated by standard 
procedures. Permission for these studies was obtained from the 
local medical ethics committee (Commissie Mensgebonden 
Onderzoek Arnhem-Nijmegen), and volunteers gave written 
informed consent. The study was conducted according to the 
Declaration of Helsinki principles.
Clinical scores
As a measure of disease severity the clinical score was 
determined by medical specialists. For psoriatic patients the PASI 
(0 to 72 scale) [30], for atopic dermatitis patients the SCORAD (0 
to 103 scale) [31] and for rheumatic arthritic patients the DAS28 
(0 to 10 scale) [32] was used to measure disease severity. Patients 
were classified as being in remission, or having low disease activity, 
moderate disease activity or high disease activity (see table 1).
Immunohistochemistry
Autopsy material and skin biopsies were fixed in 4% phosphate- 
buffered formalin and embedded in paraffin as described before 
[33]. Sections of seven micrometer were stained according to the 
avidin biotinylated-enzyme-complex method (Vector Laborato­
ries, Burlingame, CA) using a goat anti-hBD-2 serum (Abcam, 
Cambridge, UK).
RNA extraction and real-time quantitative polymerase 
chain reaction
RNA from a variety of organs that included many epithelial 
tissues, was available from autopsy material of one individual. For 
this reason the qPCR data in figure 1 have only n = 1 for most 
organs. Additional RNA samples from lung (8), kidney (2), heart 
(1), testis (1), spleen (1) and liver (1), normal (5) and inflamed 
epidermis (7) and inflamed synovium (5) were obtained from 
different individuals and analyzed for beta defensin expression. 
Variability between the different samples from one type of organ 
was low, and similar profiles of differential expression of beta 
defensins 1, 2 and 3 were found. W hen multiple samples per organ 
were available, expression values are given as mean and SD in 
figure 1.
RNA was extracted from twenty-four different normal human 
tissues, punch biopsies and cultured human keratinocytes, and first 
strand cDNA was synthesized using an input of 1 mg of RNA with 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according 
to the manufacturer’s recommendation. The reverse transcriptase 
product was used as a template for quantitative real-time PCR 
amplification of genes of interest hBD-1, hBD-2 and hBD-3 and 
the housekeeping gene hum an ribosomal phosphoprotein P0 
(RPLP0) with the M yiQ  Single-Color Real-Time Detection 
System for quantification with Sybr Green and melting curve 
analysis (Biorad, Richmond, CA). Expression of target genes was
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Table 1. Disease severity and serum hBD-2 of patients and controls
Diagnosis Disease severity Disease score N Serum hBD-2 (ng/ml)
Controls n.a. n.a. 70 0.21 60.17
Psoriasis remission, PASI 0-1 0.460.4 3 0.6460.36
low, PASI 1-10 6.062.7 18 4.564.6
moderate, PASI 10-20 15.1 62.8 12 11.569.1
high, PASI.20 30.263.6 5 84.2680.0
Atopic dermatitis remission, SCORAD 0-5 060 2 0.1060.01
low, SCORAD 5-15 12.062.8 2 0.1260.03
moderate, SCORAD 15-40 27.969.4 6 1.0560.95
high, SCORAD>40 47.665.0 2 1.3960.74
Rheumatoid arthritis remission, DAS28 0-2.6 2.1 60.5 10 0.3360.16
low DAS28, 2.6-3.2 2.960.1 5 0.3460.19
moderate, DAS28 3.2-5.1 4.260.6 16 0.51 60.41
high, DAS28>5.1 6.060.4 9 0.8360.59
Serum hBD-2 levels were determined by ELISA. Analysis of variance on log transformed data showed that there was a significant correlation between disease severity 
and serum hBD-2 levels in psoriasis patients (p < 2 x1 0 —5). Disease scores and serum hBD-2 concentration are given as mean and SD. n.a. not applicable. 
doi:10.1371/journal.pone.0004725.t001
Figure 1. Analysis of beta-defensin mRNA expression in normal and inflamed human tissues. Quantitative real-time PCR was performed 
on RNA of normal human tissues (mostly obtained from one individual), purified epidermis from skin biopsies of healthy controls, psoriasis patients 
and atopic dermatitis patients, and inflamed synovium from rheumatoid arthritis patients. Expression of target genes was normalized to that of 
RPLP0. For graphical representation all values were expressed relative to hBD-2 in tongue, which was set at unity [34]. Primer sequences and 
efficiency of amplification are given in supplemental table S1. For details on normal human tissues see materials and methods. Bars represent mean 
and SD.
doi:10.1371/journal.pone.0004725.g001
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normalized to that of RPLP0. This housekeeping gene was not 
found to be subject to regulation in keratinocyte cultures, 
irrespective of stimulation or diagnosis, and is more reliable than 
other reference genes such as ACTB (actin) or GAPDH (data not 
shown). RPLP0 levels of the various tissues did not show large 
differences (mean and SD of Ct values of normal hum an tissues 
was 21.761.6). The deltaCt values were used for statistical 
analysis. For graphical representation (figure 1) all values were 
expressed relative to hBD-2 in tongue, which was set at unity [34]. 
This allows comparison of all genes and all tissues for relative 
expression levels. Primer sequences (Biolegio, Nijmegen, The 
Netherlands) and efficiency of amplification are given in 
supplemental table S1.
Production of recombinant hBD-2 and rabbit antiserum
A hBD-2 PC R  product from cDNA derived from cultured 
keratinocytes was cloned into pG EX -2T vector (Amersham 
Pharmacia Biotech, Uppsala, Sweden), expressed as a GST- 
hBD-2 fusion protein in Escherichia coli and affinity-purified. 
Commercial recombinant hBD-2 (Peprotech, Rocky Hill, NJ) 
was cross-linked to ovalbumin, using glutaraldehyde, to increase 
immunogenicity. This preparation was dialysed against phosphate- 
buffered saline and emulsified with complete Freund’s adjuvant to 
immunize rabbits to generate polyclonal serum. Animals were 
boostered with GST-hBD-2, and blood was obtained for serum 
preparation.
ELISA
Affinity-purified goat anti-hBD-2 (Abcam) was used to coat 96- 
well microtiter plates. After blocking in 1% (v/v) bovine serum 
albumin, serum samples were applied in a serial 2-fold dilution 
range, followed by our rabbit anti-hBD-2 as a second antibody, 
and detection by the ABC kit (Vector). All steps were followed by 
appropriate washing in phosphate-buffered saline with 0.05% (v/ 
v) Tween-20. The serum hBD-2 concentrations were read from a 
calibration curve of recombinant hBD-2 (Peprotech). The 
detection limit of this ELISA was 0.03 ng/m l, using recombinant 
hBD-2 (Peprotech) for calibration. Anti-hBD-2 antibodies were 
checked for specificity against hBD-2, and we found that 
recombinant hBD-1 (Abcam) and hBD-3 (Abcam) were not 
recognized. We found no evidence for circadian differences in 
serum hBD-2 in healthy individuals (data not shown). Serum hBD-
2 was found to be stable upon storage at — 20°C. No large 
differences were found for individuals from whom we had serum 
samples taken with a two-year interval. Commercially available 
ELISA kits for hBD-2 and hBD-3 were purchased from Phoenix 
(Belmont, CA) and performed according to manufacturer’s 
recommendations. The detection limits for these assays were 
0.05 and 0.1 ng /m l respectively, using synthetic hBD-2 and hBD-
3 for calibration.
Genotyping of defensin copy number
Genomic DNA from seventy control individuals without 
inflammatory skin disease was analyzed for genomic copy number. 
Most of these individuals were analyzed by three methods: 
MAPH, RED V R and PR T  as described previously in great detail 
[16,23,35]. These analyses were used to obtain the best estimate of 
integral copy number.
Three-dimensional reconstructed skin
Reconstructed skin was generated as described before [36]. 
Briefly, de-epidermized hum an dermis (DED) of 0.8 mm thickness 
and 8 mm diameter was used as a scaffold for keratinocytes in
tissue culture inserts in a 24-well plate. These were cultured 
submerged for three days, and subsequently the medium level was 
lowered to allow air-exposure to induce terminal differentiation. 
After seven days of air exposure a fully stratified epidermis has 
developed that expresses all normal differentiation markers, but is 
negative for psoriasis-associated genes like CK16, SKALP/elafin 
and hBD-2. At this point a mixture of 10 ng/m l IL-1a, 5 ng/m l 
T N Fa and 5 ng /m l IL-6 is added for 72 hours, which induces 
high expression levels of psoriasis-associated genes. The culture 
medium, 450 ml per culture, was harvested and changed at 24, 48 
and 72 hours and used for hBD-2 ELISA. Two different donors 
for human keratinocytes were used.
Statistics
All statistical analyses were performed using the Statistica 
software package version 7, Statsoft Inc. Analysis of variance was 
performed on log transformed data of serum hBD-2. Analysis of 
qPCR data was done on deltaCt values.
Modelling of epidermal hBD-2 concentrations
Fick’s law for mass transport was applied. For the diffusion 
coefficient (D) of hBD-2 we used 1.44x10—10 m 2/sec as 
experimentally determined for bovine pancreatic trypsin inhibitor 
(BPTI) [37], a protein of similar mass and isoelectric point as hBD-
2, or we used an approximation based on G raham ’s law using the 
known value for BSA (10—10 m 2/sec). The hBD-2 production) in a 
reconstructed skin model stimulated with proinflammatory 
cytokines was used estimate the concentration in the epidermal 
compartment in vitro, as an approximation of the concentration in 
psoriatic epidermis. See supplemental text S1 and supplemental 
figure S1 for details.
Results
Expression of beta-defensin mRNA and protein in normal 
tissues and inflamed skin
Although expression of beta-defensins in some hum an tissues 
has been documented before, we wanted to obtain a comprehen­
sive picture of beta-defensin tissue distribution in order to estimate 
which specific tissues would contribute to systemic protein levels. 
We performed a qPCR analysis of two beta-defensin genes that are 
contained in the repeat on chromosome 8 (DEFB4 and DEFB103) 
and one beta-defensin outside the repeat (DEFB1). Figure 1 shows 
that hBD-1 mRNA is widely expressed whereas significant levels of 
hBD-2 are predominantly found in oral epithelia. hBD-3 is 
expressed more broadly than hBD-2 as it is also found at low levels 
in normal epidermis and a few other tissues. As indicated in 
figure 1 (log scale) hBD-2 expression levels in lesional psoriatic 
epidermis are extremely high compared to any other tissue. hBD-2 
mRNA expression in atopic dermatitis is also increased, compared 
to normal skin where it is undetectable. We analyzed the 
expression of hBD-2 at the protein level by immunohistochem- 
istry. Figure 2A-E confirm the moderate expression levels in 
tongue and plantar epidermis, and the absence of expression in 
normal skin. The extremely high mRNA expression level in 
psoriatic epidermis was indeed reflected by high levels of protein as 
we have described before [10].
Serum hBD-2 levels in healthy volunteers correlate with 
genomic copy number
As a next step we wanted to make a quantitative determination 
of systemic defensin protein levels. Defensins are secreted proteins 
that will easily pass basal membranes, and we expected that
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4725
ß-Defensins in Psoriasis
Figure 2. Immunolocalization of hBD-2 in human epithelia. Immunohistochemical staining of normal human tissues (tongue, plantar skin and 
trunk skin, A-C) with a polyclonal rabbit antiserum against recombinant hBD-2. Note that protein data largely follow the mRNA data demonstrating 
the absence in normal skin, low expression in tongue and plantar skin. Bar = 100 mm. Control sections stained with pre-immune serum were negative 
(not shown).
doi:10.1371/journal.pone.0004725.g002
epithelium-expressed defensins would reach the circulation and 
could be measured in serum by ELISA. O n the basis of the limited 
expression of hBD-2 in normal hum an tissues, as demonstrated in 
figure 1, we expected low levels of protein in normal human 
serum. We developed and validated an ELISA that was sensitive 
and specific for hBD-2 to allow measurement of low serum hBD-2 
levels. In addition, commercially available ELISA kits were used to 
measure hBD-2 and hBD-3 protein in serum. We have previously 
shown that most beta-defensin genes on 8p23.1 (including those 
that encode hBD-2 and hBD-3) are subject to copy number 
variation. So far no studies have been published that investigated 
the relation between copy number and protein expression. Here 
we selected 70 healthy individuals without inflammatory skin 
disease, that were typed for beta-defensin copy number using 
multiplex amplifiable probe hybridization (MAPH), restriction 
enzyme digest variant ratio (REDVR) and paralogue ratio test 
(PRT). In  the normal population, copy number classes of 3 to 5 
defensin repeats per diploid genome are the most prevalent. We 
selected individuals to include sufficient numbers of the more rare 
copy classes of 2 and 6 to allow analysis of correlation between 
genomic copy number and serum hBD-2 protein. Figure 3 shows 
that there is a modest but highly significant correlation between 
copy number and hBD-2 protein concentration in serum. No 
correlation between serum hBD-2 and age or gender was found. 
Low hBD-2 levels were found up to 0.80 ng /m l in these human
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Figure 3. Correlation between serum hBD-2 protein levels and 
genom ic copy number. Serum hBD-2 protein levels of 70 healthy 
controls (determined by ELISA) were plotted against the genomic copy 
number of the beta-defensin repeat on chromosome 8p23, as 
determined by MAPH, REDVR and PRT. A significant linear correlation 
was found. Pearson's R = 0.46 and p < 7x10~ 5. 
doi:10.1371/journal.pone.0004725.g003
sera (mean and SD: 0.2160.17 ng/m l, see table 1), but clearly the 
variance is only partially explained by copy number. A similarly 
weak correlation (Pearson’s R = 0 .4 , p = 0.001) between copy 
number and serum protein was found using a commercially 
available hBD-2 ELISA, although absolute levels of hBD-2 
appeared to be higher for the commercial kit, which was probably 
due to the difference in standards used (not shown). hBD-3 serum 
levels of individuals without inflammatory skin disease were all 
below the detection limit (0.1 ng/ml). These data show that hBD-2 
(but not hBD-3) can be measured in normal hum an serum, and 
that these uninduced levels are at least in part determined by 
genomic copy number.
hBD-2 serum levels of psoriasis patients correlate with 
clinical severity
Because of the modest expression of hBD-2 mRNA in most 
normal tissues we expected relatively low levels of hBD-2 protein in 
the circulation, as was indeed found by ELISA in control individuals 
(figure 3). In view of the huge increase of hBD-2 mRNA in lesional 
psoriatic epidermis, the inflamed skin of psoriasis patients was likely 
to cause increased systemic levels of hBD-2 protein. We measured 
hBD-2 in sera of 38 psoriasis patients in a range of clinical severity as 
determined by the Psoriasis Area and Severity Index (PASI) score 
(see table 1). We could indeed demonstrate high levels of serum 
hBD-2 in psoriasis patients, which were found to be about 400-fold 
increased in severely affected patients compared to healthy 
individuals (see table 1). A significant effect of disease severity on 
serum hBD-2 was found by analysis of variance (p< 2x10 ). 
Figure 4 shows that there is a strong linear correlation between PASI 
score and the log-transformed serum hBD-2 concentration. Strongly 
increased levels were also found in the urine of psoriasis patients 
whereas hBD-2 could not be detected in urine of healthy controls. 
Urinary hBD-2 levels were showed strong interindividual variation 
(2.2+3.2 ng/ml). These findings suggest that increased systemic 
levels are derived from high cutaneous production. It is obvious from 
figure 4 that the clinical severity in psoriasis patients is a far stronger 
determinant of hBD-2 serum concentration than copy number for 
uninduced levels in healthy controls (figure 3). There were 
insufficient numbers of informative psoriasis patients from whom 
defensin copy numbers and PASI scores were available, to make a 
reliable estimate of the effect of copy number and disease severity on 
hBD-2 levels. Remarkably, only in a minority of psoriasis patients we 
could demonstrate hBD-3 levels that exceeded the detection limit of 
the assay (not shown).
To investigate if high systemic hBD-2 levels could be caused by 
inflammation per se, irrespective of the tissue localization, we 
compared serum hBD-2 levels in psoriasis patients with that of 40 
patients with rheumatoid arthritis (RA). Low hBD-2 serum levels
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Figure 4. Correlation between serum hBD-2 protein and PASI 
score. Serum hBD-2 protein levels of 38 psoriasis patients of varying 
disease severity were plotted against their PASI score. A significant 
linear correlation was found. Pearson's R = 0.82, p < 4 x1 0 210. 
doi:10.1371/journal.pone.0004725.g004
were found in RA patients with low to high disease activity and in 
RA patients that were in remission (see table 1). In the combined 
RA patients with moderate to high disease activity, a small but 
significant increase of serum hBD-2 was found compared to the 
control group (t-test, p < 1 0 _5). qPCR analysis of synovial tissue 
from RA patients with active disease showed that the synovium is 
unlikely to be the source of this small increase in hBD-2 protein, as 
no mRNA for hBD-2 could be detected (see figure 1). No 
significant correlation was found between serum hBD-2 and 
clinical severity as determined by Disease Activity Score (DAS28).
As previously reported [10], hBD-2 protein is expressed at low 
to undetectable levels (immunohistochemistry) in lesional atopic 
dermatitis, despite strong induction at the mRNA level. In sera 
from 8 patients with moderate to severe atopic dermatitis we found 
that, although serum hBD-2 levels were significantly higher than 
in control sera (t-test, p <  10 5), they were far lower than in sera of 
psoriasis patients of similar disease severity (see table 1). A 
significant linear correlation between log-transformed serum hBD- 
2 and atopic dermatitis disease severity, as determined by 
SCORing Atopic Dermatitis (SCORAD), was found (Pearson 
r = 0.7, p<0.01), suggesting that also in atopic dermatitis increased 
systemic levels are derived from increased cutaneous production.
Serum hBD-2 is a disease marker in individual psoriasis 
patients
As serum hBD-2 showed a correlation with disease activity over a 
group of psoriasis patients, we next investigated if hBD-2 levels 
correlate with clinical status ofindividual patients. Serum hBD-2 was 
measured in 15 patients that participated in clinical studies for which 
PASI scores and serum was available on two different occasions over 
a 6-18 week interval. Figure 5 shows that there is a strong 
correlation between the change in hBD-2 (AhBD-2) and change in 
PASI score (APASI) in eleven patients that showed clinical 
improvement and four patients that showed exacerbation of disease.
Estimation of in vivo hBD-2 concentration in psoriatic 
epidermis using in vitro reconstructed skin
The high serum levels of hBD-2 in psoriasis patients (up to 
190 ng/ml), which we interpret to be derived from local production 
by the keratinocytes, suggest that the concentrations to which 
keratinocytes and infiltrated cells in the epidermis and papillary 
dermis are exposed must be several orders of magnitude higher.
Figure 5. Correlation between the change in serum hBD-2 
concentration and change in clinical score. Serum hBD-2 protein 
levels of 15 patients for which PASI scores and serum was available on 
two different occasions over a 6-18 week interval, were plotted against 
the change in PASI score (APASI). A significant linear correlation was 
found. Pearson R = 0.74, p<0.002. Note that there was a decrease in 
serum hBD-2 in most patients that showed clinical improvement 
(negative APASI) and an increase in serum hBD-2 in a few patients that 
showed exacerbation (positive APASI). 
doi:10.1371/journal.pone.0004725.g005
Based on in vitro studies, the concentrations required to have a 
relevant biological effect would vary between 0.1 and 100 mg/ml. 
Because these local tissue concentrations are difficult to estimate 
directly from in vivo data, we measured the production of hBD-2 in 
reconstructed skin as a model for human epidermis. Human 
reconstructed skin equivalents were obtained as described previously 
[38], and stimulated with IL-1a, TN F-a and IL-6. This cytokine 
mixture was recently found to be optimal for induction of a psoriatic 
phenotype in vitro, as witnessed by high expression levels of CK16, 
SKALP/elafin and hBD-2 [36]. qPCR analysis of isolated epidermal 
sheets indicated that hBD-2 mRNA levels (determined as deltaCt 
values) in these cultures were much higher than in keratinocytes from 
submerged cultures (not shown), and reached similar high values as 
found in epidermal sheets from lesional psoriatic skin (see figure 1). 
Figure 6 shows hBD-2 protein expression by differentiated 
keratinocytes in the reconstructed skin model stimulated with pro- 
inflammatory cytokines. We collected culture medium from 
cytokine-stimulated reconstructed skin of two donors during 
24 hours starting two days after addition of the cytokine mix. Using
Figure 6. Induction of hBD-2 protein expression in reconstruct­
ed skin by proinflammatory cytokines. Expression of hBD-2 in 3-D 
reconstructed skin following stimulation with psoriasis-associated 
cytokines (10 ng/ml IL-1a, 5 ng/ml TNFa and 5 ng/ml IL-6) for 72 hours. 
Note that without stimulation there is no hBD-2 expression (A), whereas 
the cytokine mixture induces high expression levels that are secreted 
into the underlying culture medium (147 ng/ml in 24 h). Part of the 
hBD-2 protein remains adsorbed to the dermal matrix as witnessed by 
the staining of structures in the dermis (B). Bar=100 mm. 
doi:10.1371/journal.pone.0004725.g006
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ELISA we found that these cultures, consisting of 8 mm diameter 
skin constructs, secreted approximately 66619  ng hBD-2 per 
24 hours into the tissue culture medium (mean and SD of four 
cultures). We derived the local epidermal concentration using an 
approximation based on the known diffusion coefficient of a small 
cationic protein in aqueous solution (see supplemental materials for 
assumptions and dimensions of the system, used for modelling). 
Alternatively, a theoretical value for the diffusion coefficient was 
obtained based on Graham’s law (see supplemental materials). The 
most conservative estimation of the hBD-2 local concentration in the 
compartment of the epidermis was 1.2 m g/m l (0.3 mM), which is 
far higher than concentrations required for in vitro antimicrobial 
activity, or those reported for chemotactic activity towards T-cells 
and dendritic cells.
D iscussion
Psoriasis is associated with increased beta-defensin genomic 
copy number but no quantitative information on defensin protein 
expression in vivo, as a function of copy number or disease status 
was available. We now present evidence that both genomic copy 
number and epidermal activation by psoriasis-associated cytokines 
determine expression levels of hBD-2. We conclude that these 
increased circulating hBD-2 levels in patients are derived from 
cutaneous production, indicating that local hBD-2 concentrations 
in psoriatic epidermis are likely to be extremely high. Extrapola­
tion from an in vitro model system suggests that the concentration 
in the epidermis or papillary dermis (0.3 mM) by far exceeds the 
concentrations required to be antimicrobial (2.5 to 25 mM) and 
chemotactic in vitro (250 nM) as described previously by others 
[9,39].
A number of studies have reported expression of hum an beta- 
defensins in various tissues, including normal skin, inflamed skin 
and non-cutaneous epithelia, using semi-quantitative R T-PCR or 
immunohistochemistry. Here we have quantified circulating levels 
of hBD-2 and hBD-3 by ELISA in healthy volunteers and patients 
with inflammatory diseases. To assess which of the normal human 
epithelia would contribute to steady state systemic protein levels, 
we first performed a comprehensive qPCR analysis of the three 
major epidermal defensins, hBD-1, -2 and -3 in a large panel of 
hum an tissues. As shown in figure 1, hBD-1 mRNA is widely 
expressed, and is not subject to regulation by inflammation, as it is 
not highly induced in psoriatic skin. Measurement of hBD-1 
protein in serum would have provided a reference value for a beta- 
defensin that is expected to be rather constant as it is not present 
on the psoriasis-associated repeat. We were however unsuccessful 
in measuring hBD-1 protein by ELISA (not shown). hBD-2 
mRNA appears to be expressed constitutively by a few tissues (e.g. 
oral epithelia), and was indeed found at the protein level albeit 
weakly (figure 2). hBD-2 is absent from normal trunk skin, but it is 
expressed at low levels in plantar skin. Consequently, serum hBD-
2 levels in healthy individuals are very low (less than 1 ng per ml). 
In addition to our own ELISA (recombinant hBD-2 for 
calibration), we also used a commercial hBD-2 ELISA kit that 
uses synthetic hBD-2 for calibration. Although there was a good 
correlation between the data of both assays (Pearson r = 0.9), the 
commercial ELISA yielded apparent hBD-2 serum concentrations 
10-fold higher than our ELISA. We found that this was caused by 
a difference in immunoreactivity of the calibration standards used. 
We used the values obtained with recombinant hBD-2 throughout 
this paper, as a conservative estimate of hBD-2 concentration.
As shown in figure 3, genomic copy number only explains part 
of the variance in serum hBD-2 levels. This is unlikely to be caused 
by experimental error. We considered sampling error as a
potential cause, but we did not find variation in serum hBD-2 
level depending on the time of blood sample collection (early 
morning versus late afternoon). Longitudinal data showed only 
minor fluctuation of serum hBD-2 levels in blood taken with two- 
year intervals (not shown). We speculate that the large variation of 
protein levels in each copy class could be caused by variation in 
expression regulation, or alternatively, by genetic variation in the 
defensin copies themselves. Although there is currently no 
information on the existence of non-functional gene copies within 
the repeat, this would obviously affect the gene-protein correla­
tion, and it could also affect the observed association with 
psoriasis, which clearly requires further investigation.
Although our findings indicate that uninduced hBD-2 produc­
tion is subject to gene dosage effects, the high systemic serum levels 
in psoriasis patients are caused by disease activity itself. We think 
this indicates that hBD-2 can be used as an objective, quantitative 
marker for disease activity in psoriasis. There are very few reliable 
serum markers for disease activity in psoriasis. Candidate proteins 
that are overexpressed in lesional epidermis include SKALP/elafin 
and psoriasin/S100A7, but only SKALP/elafin was found to 
correlate with disease activity [40,41]. Previous studies have 
suggested that conventional surrogate markers for disease activity 
in rheumatoid arthritis and psoriatic arthritis, such as erythrocyte 
sedimentation rate and levels of C-reactive protein (CRP) are not 
useful for chronic plaque psoriasis [42]. For this reason we looked 
at the correlation between PASI scores and CRP in a cohort of our 
own patients that were monitored over time. We did not find a 
significant correlation between CRP and PASI for 1305 patient 
visits (data not shown), again suggesting that serum hBD-2 could 
be a convenient way to monitor disease activity or therapeutic 
effects.
At the tissue level, hBD-2 secretion will be determined both by 
copy number and by stimulation with proinflammatory cytokines. 
O ur data also suggest that disease activity in atopic dermatitis is 
correlated with serum hBD-2. However, the epidermal expression 
in atopic dermatitis is far lower than in psoriasis [10,11], 
presumably resulting from the distinct cytokine environments of 
these diseases [8,28]. We could indeed show that Th2 cytokines do 
not induce hBD-2 expression in cultured keratinocytes [18] and 
that Th2 cytokines repress the Th1 induced expression (not shown 
here), as was previously shown for hBD-3 [43]. An additional level 
of regulation of hBD-2 expression is the responsiveness of cells to 
pro-inflammatory cytokines. We have recently shown that cell- 
autonomous differences exist between keratinocytes of psoriasis 
patients, atopic dermatitis patients and controls with respect to 
innate immune responses following Th1 cytokine stimulation [18]
. We would speculate that there are apparently three mechanisms 
that contribute to high levels of hBD-2 in psoriatic epidermis: a 
dominant Th1 or Th17 cytokine profile, increased cell-autono­
mous responsiveness to cytokine stimulation, and high defensin 
genomic copy number. Although defensins are endowed with 
cytokine-like properties themselves, there is no information on a 
possible autocrine effect of hBD-2 on keratinocytes whereby it 
would induce or sustain its own production. This is clearly an area 
worth investigating.
Several studies have demonstrated the biological activities of 
hum an and mouse beta-defensins, such as antimicrobial activity 
[9], chemotaxis of T-cells and dendritic cells [44], and activation 
of TLR4 [45]. In general, many antimicrobial proteins appear to 
be endowed with other immune-modulatory activities [46-48]. 
These findings have raised the intriguing possibility that beta- 
defensins are part of the innate immune system that provides a link 
between the epithelium and the adaptive immune system. This 
would fit the emerging concept of inflammatory epithelial diseases
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[14] that is supported by findings on the genetics of atopic 
dermatitis [15], C rohn’s disease [49] and celiac disease [50]. This 
would also explain the clinical observation that both T-cell 
directed drugs (cyclosporine A, UVB, some biologicals) and 
keratinocyte-directed drugs (retinoids, vitamin D3 derivatives) are 
effective in the treatm ent of psoriasis.
The defensin concentrations used in in vitro studies to 
demonstrate their biological activity and their relevance for the 
in vivo situation, should be interpreted with some caution. For 
example, the antimicrobial activity of hBD-2 can only be 
demonstrated at low salt conditions [51], at least in low 
micromolar concentrations. Notwithstanding these considerations, 
we attempted to make an estimate of the actual hBD-2 
concentration in an active psoriatic lesion. Although there are 
some caveats associated with modelling of the in vivo tissue 
concentrations based on an in vitro reconstructed skin model, it is 
clear that the hBD-2 levels in epidermis and papillary dermis are 
well above the minimal concentrations that would cause a 
biological effect in an experimental setting, even allowing for an 
error of one order of magnitude. Remarkably, we found very little 
hBD-3 protein in the circulation. Only in a few psoriasis patients 
we observed detectable levels up to 0.5 ng/m l, which is 160-fold 
lower than the hBD-2 concentration in patients with severe 
psoriasis. W hether this also reflects low hBD-3 protein production 
in the epidermis requires further investigation.
O ur previous finding on the genetic association of psoriasis with 
the defensin cluster did not allow discrimination between the seven 
defensins or defensin-like genes contained in the repeated segment. 
O n the basis of available expression data we predicted that hBD-2 
and hBD-3 would be the best candidates. Here we provide further 
evidence that, based on copy number dependent and disease- 
specific gene expression, high cutaneous protein levels and its 
known proinflammatory properties, hBD-2 is one of the strongest 
psoriasis candidate genes contained in the beta defensin cluster on 
chromosome 8.
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